150 related articles for article (PubMed ID: 34527209)
1. Concurrent Diagnosis of Acute Myeloid Leukemia and Symptomatic COVID-19 Infection: a Case Report Successfully Treated with Azacitidine-Venetoclax Combination.
Taurino D; Frigeni M; Grassi A; Cavallaro G; Salmoiraghi S; Spinelli O; Rambaldi A; Lussana F
Mediterr J Hematol Infect Dis; 2021; 13(1):e2021057. PubMed ID: 34527209
[TBL] [Abstract][Full Text] [Related]
2. Successful Bridging to Allogeneic Hematopoietic Stem Cell Transplantation by Azacitidine and Venetoclax in a Case of Acute Myeloid Leukemia With t(3;3)(q21.3;q26.2) Developed Early After Orthotopic Heart Transplantation.
Ueda T; Fujita J; Akazawa Y; Kawamura A; Matsui T; Hino A; Kusakabe S; Sudo T; Fukushima K; Yokota T; Miyagawa S; Sakata Y; Hosen N
Transplant Proc; 2023 Apr; 55(3):711-714. PubMed ID: 37012142
[TBL] [Abstract][Full Text] [Related]
3. Durable remission of acute myeloid leukemia in an elderly patient following a limited course of azacitidine and venetoclax.
Ehsan H; Iqbal Q; Masood A; Grunwald MR
Leuk Res Rep; 2022; 18():100345. PubMed ID: 36051639
[TBL] [Abstract][Full Text] [Related]
4. Acute Myeloid Leukemia Harboring the t(16;21)(p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation.
Teshima K; Ikeda S; Abe K; Yamada M; Takahashi N
Cureus; 2023 Jul; 15(7):e42215. PubMed ID: 37602052
[TBL] [Abstract][Full Text] [Related]
5. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.
Winters AC; Gutman JA; Purev E; Nakic M; Tobin J; Chase S; Kaiser J; Lyle L; Boggs C; Halsema K; Schowinsky JT; Rosser J; Ewalt MD; Siegele B; Rana V; Schuster S; Abbott D; Stevens BM; Jordan CT; Smith C; Pollyea DA
Blood Adv; 2019 Oct; 3(20):2911-2919. PubMed ID: 31648312
[TBL] [Abstract][Full Text] [Related]
6. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
7. Hypomethylating agents+venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy - novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country.
Mirgh S; Sharma A; Shaikh MRMA; Kadian K; Agrawal N; Khushoo V; Mehta P; Ahmed R; Bhurani D
Am J Blood Res; 2021; 11(3):290-302. PubMed ID: 34322294
[TBL] [Abstract][Full Text] [Related]
8. Meta‑analysis of the efficacy of venetoclax and azacitidine combination therapy and azacitidine monotherapy for treating acute myeloid leukemia.
Xie Y; Wei X; Wang W; Liao C; Han P; Yu Y
Exp Ther Med; 2024 Apr; 27(4):164. PubMed ID: 38476897
[TBL] [Abstract][Full Text] [Related]
9. The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19.
Cristiano A; Palmieri R; Fabiani E; Ottone T; Divona M; Savi A; Buccisano F; Maurillo L; Tarella C; Arcese W; Voso MT
Mediterr J Hematol Infect Dis; 2022; 14(1):e2022041. PubMed ID: 35615323
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings.
Taniguchi S; Yamauchi T; Choi I; Fukuhara N; Potluri J; Salem AH; Hong WJ; Honda H; Nishimura Y; Okubo S; Usuki K
Jpn J Clin Oncol; 2021 May; 51(6):857-864. PubMed ID: 33712849
[TBL] [Abstract][Full Text] [Related]
11. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
[TBL] [Abstract][Full Text] [Related]
12. Case report: Venetoclax therapy in a boy with acute myeloid leukemia in Shwachman Diamond syndrome.
Naviglio S; Grasso AG; Iacono C; Zanella G; Kiren V; Giurici N; Verzegnassi F; Maximova N; Rabusin M
Front Pediatr; 2022; 10():1059569. PubMed ID: 36699295
[TBL] [Abstract][Full Text] [Related]
13. The successful combination of grapefruit juice and venetoclax in an unfit acute myeloid leukemia patient with adverse risk: A case report.
Long Z; Ruan M; Wu W; Zeng Q; Li Q; Huang Z
Front Oncol; 2022; 12():912696. PubMed ID: 36248996
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report.
Liu B; Narurkar R; Hanmantgad M; Zafar W; Song Y; Liu D
Front Med; 2018 Oct; 12(5):593-599. PubMed ID: 29785506
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy.
Richard-Carpentier G; DiNardo CD
Ther Adv Hematol; 2019; 10():2040620719882822. PubMed ID: 31692757
[TBL] [Abstract][Full Text] [Related]
16. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
[TBL] [Abstract][Full Text] [Related]
18. The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia.
Abbott D; Cherry E; Amaya M; McMahon C; Schwartz M; Winters A; Schowinsky J; Jordan CT; Smith C; Gutman JA; Pollyea DA
Leuk Lymphoma; 2021 Jun; 62(6):1466-1473. PubMed ID: 33375853
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax with Azacitidine Induced Tumor Lysis Syndrome in an Elderly Patient with Acute Myeloid Leukemia: A Case Report.
Kim M; Bang HJ; Song GY; Ahn SY; Jung SH; Song YS; Ahn JS
Electrolyte Blood Press; 2021 Dec; 19(2):46-50. PubMed ID: 35003285
[TBL] [Abstract][Full Text] [Related]
20. Benefit of the Reduced Dose Combination of Azacitidine and Venetoclax in an Elderly Patient With Acute Myeloid Leukemia.
Fujino K; Ureshino H; Yoshida T; Ichinohe T
Cureus; 2023 May; 15(5):e39481. PubMed ID: 37362503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
